Packaging concept. Final appearance may change.
Malibu Wellness
GLPWell Digest
Launch price coming soon
Coming soon — a six-ingredient digestive wellness concept.
GLPWell Digest brings together botanical extracts, zinc L-carnosine, a specified probiotic strain and an enzyme.
Pack target: 60 capsules. Formula reference: 2 capsules per target serving; 30 target servings.
The Malibu collection is in development. Only products with confirmed availability can be added to the cart.
Our manufacturing commitment
USA made · cGMP manufacturing
Formula and research details
Coming soon — a six-ingredient digestive wellness concept.
GLPWell Digest brings together botanical extracts, zinc L-carnosine, a specified probiotic strain and an enzyme.
Pack target: 60 capsules. Formula reference: 2 capsules per target serving; 30 target servings.
Formula development targets
| Ingredient | Per capsule | Per 2 capsules |
|---|---|---|
| Ginger rhizome extract (25–30% total gingerols) | 20 mg | 40 mg |
| Artichoke leaf extract (>20% caffeoylquinic acids; >5% flavonoids; >5% cynaropicrin) | 100 mg | 200 mg |
| GutGard licorice extract (at least 10% flavonoids and 3.5% glabridin; no more than 0.5% glycyrrhizin) | 75 mg | 150 mg |
| Zinc L-carnosine complex | 37.5 mg | 75 mg |
| Bacillus coagulans MTCC 5856 | 1 billion CFU | 2 billion CFU |
| Alpha-galactosidase | 300 GALU | 600 GALU |
The zinc complex targets approximately 17 mg elemental zinc per two capsules, subject to assay. Probiotic and enzyme preparation weights depend on supplier potency. Final activity and viable count specifications must be verified through shelf life.
The Malibu standard
Premium formulation, a refined daily experience, and a commitment to U.S. manufacturing and transparent product testing. We don’t formulate to be the cheapest. We formulate to be exceptional.
Research context
The ginger/artichoke study involved functional dyspepsia, not GLP-1 medication users. This six-ingredient formula has not been clinically tested in GLP-1 users; its name does not establish an effect on GLP-1, medication side effects or delayed gastric emptying.
No completed clinical trial of this finished Malibu formula is documented in the product portfolio.
Development status
Coming soon. Formula and packaging targets are in development and subject to final verification. This draft is not a final product label or directions for use. Pricing has not been set. Manufacturing records, finished-product testing and final claims must be completed before release.